In The News

Vaccination Rates Improving, Particularly Among the Seniors, but Herd Immunity is a Moving Target

As reported by Kaiser Healthcare News, last Tuesday, the United States hit another milestone with 90% of people 65 and older being at least partially vaccinated against the disease. That’s more than 49 million seniors vaccinated. Overall, 70% of adults have been inoculated, at least partly, and nearly 68% of people over 12.

Despite improved vaccination rates, another article by Medscape Medical News, reported that, “Because the Delta variant of SARS-CoV-2 spreads more easily than the original virus, the proportion of the population that needs to be vaccinated to reach herd immunity could be upwards of 80% or more, experts say. The original SARS-CoV-2 virus required an estimated 67% of the population to be vaccinated to achieve herd immunity. For Delta, those threshold estimates go well over 80% and may be approaching 90%.”

 

Pfizer says immunity can drop to 84% within four months in people who got its COVID-19 shot, further bolstering the company case for a booster

Market Watch/ By Jaimy Lee

The drug maker said this week that new data shows effectiveness can decline to about 83.7% four to six months after vaccination

The effectiveness of Pfizer’s COVID-19 shot can drop to 83.7% within four to six months after getting the second dose of its vaccine. This is the latest indication that vaccine-induced immunity to the virus can wane and some kind of boost may be necessary in the future.

New research published Wednesday as a preprint indicates that the Pfizer Inc.  shot provides 96.2% protection for the first two months, 90.1% effectiveness between the second and fourth months, and between 83.7% of protection for the fourth, fifth, and six months. 

“We will need a booster eight to 12 months from the second dose,” Pfizer CEO Albert Bourla said Wednesday, according to a FactSet transcript of the company’s second-quarter earnings call. 

The drug maker has been making the case for booster shots, citing limited data from its own clinical research and real-world data out of Israel, where Pfizer’s vaccine is the predominant shot in circulation.  “We do see—after six to eight months—more rapid waning concerning infections and mild to moderate symptoms,” Dr. Mikhail Dolsten, Pfizer’s chief scientific officer, said during the call. “Those are likely entirely, or to a large degree, dependent on antibodies and the drop in titer that we alluded to. If you raise it, you may have a good probability to reverse that waning.

Still, there’s no simple black-and-white answer to whether booster shots are needed at this time. One, there is no definitive data. The new Pfizer data is the most detailed so far, though the company plans to submit clinical data for a third dose to the Food and Drug Administration in early August.

Read Full Article

 

 

CDC Updates Mask Guidance

CNN has reported, "To prevent further spread of the Delta variant, the US Centers for Disease Control and Prevention updated its mask guidance on Tuesday to recommend that fully vaccinated people wear masks indoors when in areas with "substantial" and "high" transmission of COVID-19, which includes nearly two-thirds of all US counties. New unpublished data showing that vaccinated people infected with the Delta coronavirus variant can have as much virus as those who are unvaccinated is the primary driver for the CDC's latest mask guidance change, a source involved with the decision process told CNN. Overall, vaccinated people still play a small role in transmission and breakthrough infections are rare."

 

HEADSTRONG: Differential Diagnosis and Management of Concussion Recovery

Advanced Clinical Reasoning for Physical Therapists

Physical Therapists are leaders in determining readiness for return to activity after mTBI. This advanced collaborative learning workshop helps ensure clinicians are prepared for that responsibility. We employ evidence-informed practical information necessary for differential diagnoses of acute and post concussive disorders (PCD) using the ICF Model to identify impairments that limit activities and life role participation. Interactive learning, practice of assessment and intervention skills, and case study exercises will equip participants to improve compassionate and effective interventions in their own practice settings and populations. Interfacing with community stakeholders, multidisciplinary health team, and legal implications are all discussed. Special attention will be focused on motion-provoked dizziness, visual motion hypersensitivity, postural maladaptations, and dysautonomia including POTS. Continued support and mentorship are available to participants through electronic means.

Continuing Education Credit:
Physical Therapists: The course meets Colorado standards for 15 hours of Category I continuing competence activities (C.R.S.§ 12-41-114.6)
Occupational Therapists: The course meets Colorado standards for 15 hours PDA (C.R.S.§ 12-40.5-109.3, may use 12 hours)

When:


Course proceeds support Colorado physical therapy legislative efforts.

 

Interested in Presenting Your Poster or Platform at the 2021 Fall Conference?

DEADLINE TO SUBMIT YOUR ABSTRACT IS TOMORROW, JULY 30TH!

Share Your Research, Knowledge, and Expertise! 

We encourage all PTs, PTAs, and students to submit abstracts on case reports, special interest reports, or research projects. Abstracts submitted will be selected for presentation based on quality research and clinical relevance. 

For More Information on Submitting a Poster or Platform Proposal, click here!

 
<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 10 of 92